Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs T Rowe Price Group Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B), while T Rowe Price Group Inc trades at $104.25 (market cap $22.23B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.6× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and T Rowe Price Group Inc for 115 Days on average.
| TAK | TROW | |
|---|---|---|
Market Cap | $58.74B | $22.23B |
Volume | 3,110,994 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $19.05 | $121.68 |
52-Week Low | $13.23 | $86.19 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $86.65B | $19.43B |
Dividend Yield | 3.33% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
T. Rowe Price Group (TROW) trades at $104.07, up 0.45% with bearish technical signals but strong fundamentals including a 10.45 P/E ratio and 29.26% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 slightly missed. The company maintains robust cash flow with $704.4M net cash flow in 2025 and a dividend yield near 5% with 40 years of consecutive growth.
The stock offers value with attractive valuation metrics and consistent profitability, though technical indicators suggest near-term pressure. Key risks include market-sensitive revenue streams and net outflows, while analyst consensus at $112 target implies 7.6% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
